Latest Wound Care News

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Tissue Repair Limited has commenced patient randomisation in its Phase 3 trial of TR987®, targeting chronic venous leg ulcers, aiming to confirm promising earlier results and potentially transform wound healing treatment.

Next Science reported a 2.9% revenue increase to US$22.8 million in FY24, driven by an 85% surge in XPERIENCE™ sales, while achieving adjusted EBITDA and cashflow positivity in 4Q FY24 amid strategic cost restructuring.